These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17889191)

  • 1. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study.
    Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Rueda J; Arnau MA; Agüero J; Sánchez-Lázaro I; Ortiz V; Salvador A
    Transplant Proc; 2007 Sep; 39(7):2365-7. PubMed ID: 17889191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibitors: do they help preserve renal function?
    Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
    Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation.
    Moro JA; Almenar L; Martínez-Dolz L; Sánchez-Lázaro I; Agüero J; Salvador A
    Transplant Proc; 2008 Nov; 40(9):3034-6. PubMed ID: 19010183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
    Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
    Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
    J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
    Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
    Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus experience in heart transplantation.
    Aranda-Dios A; Lage E; Sobrino JM; Mogollón MV; Guisado A; Cabezón S; Hinojosa R; Hernández A; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
    Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
    Celik S; Doesch A; Erbel C; Blessing E; Ammon K; Koch A; Katus HA; Dengler TJ
    Transplantation; 2008 Jul; 86(2):245-50. PubMed ID: 18645486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.
    Masetti M; Rompianesi G; Montalti R; Romano A; Spaggiari M; Ballarin R; Guerrini GP; Gerunda GE
    Transplant Proc; 2008; 40(6):1947-9. PubMed ID: 18675097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of mammalian target of rapamycin inhibitors during the postoperative period after cardiac transplantation.
    Bouzas-Mosquera A; Crespo-Leiro MG; Paniagua MJ; Naya C; Grille Z; Marzoa R; Barge-Caballero E; Estévez-Cid F; Alvarez-García N; Cuenca JJ; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3027-30. PubMed ID: 19010181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on renal function of the use of sirolimus in cardiac transplantation.
    Ubilla M; Mastrobuoni S; Cordero A; Castaño S; Herreros J; Rábago G
    Transplant Proc; 2007 Sep; 39(7):2401-2. PubMed ID: 17889202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
    Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT; Danguilan RA; Cabanayan-Casasola CB; Talusan-Tomacruz Y; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
    J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.